Comprehensive Healing Blend (4-Peptide)

Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

1.92 hours

Absorption half-life assumed

0.48 hours

Reference amount for the relative scale

1 mg

• Absorption half-life is assumed to be one quarter of the slower timescale (0.48 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Product sequence and route are unresolved for a generic TB-500 entry.
• Do not transplant the full-length IV peak or half-life to the 7-residue fragment.

• A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.

  Ruff 2010:40 healthy volunteers, single 42–1260 mg IV then daily 14 days; dose-dependent half-life. The legacy 1.92 h is not a verified SC half-life.

tb-500-relative-timing-2026-10 · version 1

Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

0.285 hours

Absorption half-life assumed

0.009976653 hours

Reference amount for the relative scale

1 mg

• The faster rate is inferred to match the 0.05 h source-scoped peak time; absorption half-life 0.009976653025332967 h is a mathematical shape parameter, not separately measured.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Animal IM timing does not establish human SC absorption or elimination.
• Do not use total radiolabel half-life: the radiolabel includes metabolites and recycled amino acids.
• Rat/dog Cmax must not be scaled into a human blood estimate.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.

  Rat IM 100 microgram/kg saline BPC157: half-life 17.1 min, Tmax 3 min. The 2-person human IV pilot reports safety biomarkers, not peptide concentration calibration.

• He et al.2022, original BPC157 rat/dog PK

  Rat IM100 microgram/kg:17.1 min half-life and 3 min Tmax. Human extrapolation deliberately limited to relative timing.

• Lee and Burgess2025, two-person human IV pilot

  Safety bloodwork and vital signs; no reported BPC157 plasmaPK endpoints in the abstract.

bpc-157-relative-timing-2026-10 · version 1

Legacy 0.48 h is not established by the transporter or mouse efficacy study.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

0.48 hours

Absorption half-life assumed

0.12 hours

Reference amount for the relative scale

1 mg

• Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Cell-culture nanomolar efficacy and PepT1 uptake kinetics are not plasma concentration-time parameters.
• Oral mouse exposure cannot establish human SC F.

• PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

  Legacy 0.48 h is not established by the transporter or mouse efficacy study.

kpv-relative-timing-2026-10 · version 1

Legacy 0.96 h is unverified for administered-human intact GHK-Cu. No quantitative timing is imported from free-GHK degradation.

One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.

Timing half-life used

0.96 hours

Absorption half-life assumed

0.24 hours

Reference amount for the relative scale

1 mg

• Absorption half-life is assumed to be one quarter of the slower timescale (0.24 h); it is not a measured absorption parameter.
• A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
• Free GHK, intact GHK-Cu, total copper and endogenous baseline GHK are different analytes.
• Topical cosmetic concentrations and assay calibration ranges are not plasma Cmax.

• In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds.

  Legacy 0.96 h is unverified for administered-human intact GHK-Cu. No quantitative timing is imported from free-GHK degradation.

• 1997 original rat GHK/HK analytical PK paper

  GHK acetate given IV to rats, rapidly degraded toHK; freeGHK is not intactGHK-Cu.

ghk-cu-relative-timing-2026-10 · version 1